Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

Back

A 2-Month Safety Follow-Up Trial

NCT00741429·150 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Mannkind Corporation

This was a 2-month safety follow-up study of subjects from MannKind protocols MKC-TI-009, MKC-TI-102, MKC-TI-103 and MKC-TI-030. No study medications were administered during this trial. The adverse event data included are for the combined Safety population irrespective of previous treatments in the parent trials.

Age

18–70

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Subjects who have completed any of the 4 MKC parent trials (MKC-TI-103, MKC-TI-009, MKC-TI-102, MKC-TI-030)
Urine cotinine test of less than or equal to 100 ng/mL
Written informed consent

You may not be if

Subjects who started smoking during the 4 week follow-up phase of the parent trial
Subjects who began a new inhaled insulin regimen with an investigational drug during the 4 week follow-up phase of the parent trial and/or are participation in another clinical trial
Female subjects who are pregnant, lactating or planning on becoming pregnant
Subjects with a positive urine drug screening at Visit 1
Female subjects of child-bearing potential not practicing adequate birth control

The record

StatusCompleted

PhaseNo phase

Taking part649

StartedMay 2007

UpdatedDec 3, 2014

Conditions

Type 1 Diabetes Type 2 Diabetes

Where150

Parkway Medical Center
Birmingham, Alabama, United States
Coastal Clinical Research Inc
Mobile, Alabama, United States
Radiant Research (Phoenix)
Chandler, Arizona, United States

Clareo Health | A 2-Month Safety Follow-Up Trial